Defibrillator Market: Growth, Size, Share, and Trends

Cardiovascular disease (CVD) is rising globally, driven by hypertension, obesity, diabetes, and aging populations. According to the American Heart Association, in the US, over 61% of adults are projected to have CVD by 2050, with hypertension alone expected to affect 184 million people. In Asia, lifestyle changes and genetic susceptibility are fueling rapid growth, with India recording 20–50% higher coronary artery disease mortality than global averages. These factors highlight the growing importance of cardiac defibrillators in managing sudden cardiac events.

Defibrillators, including Automated External Defibrillators (AEDs) and Implantable Cardioverter Defibrillators (ICDs), have faced frequent product recalls in recent years, often due to manufacturing defects, software errors, battery issues, or electrode connectivity failures that can delay or prevent shock delivery. Some recalls have been classified as FDA Class I, indicating serious risk of injury or death. Major manufacturers such as Medtronic (Ireland), Stryker (US), and ZOLL Medical (US) have issued recalls over problems like power supply failures and unexpected shutdowns. Due to manufacturing flaws in 2024, the FDA recalled several Medtronic devices, including Cobalt HF Quad CRT-D MRI, Crome HF Quad CRT-D MRI, and Evera S VR. While recalls protect patient safety, they also erode clinician trust, disrupt supply chains, and emphasize the need for stricter quality control and ongoing surveillance.

Emerging economies present major growth opportunities for the defibrillator market, supported by the rising prevalence of cardiovascular disease and stronger healthcare infrastructure. The American Heart Association (AHA) projects cardiovascular events in China to grow by over 50% between 2010 and 2030. Market players strategically target increasing their footprint in these countries to take advantage of the strong growth prospects for defibrillator devices in emerging markets. In March 2024, Nihon Kohden Corporation opened Nihon Kohden Vietnam, a wholly owned subsidiary of its Singapore office, to facilitate regulatory registration and drive the sales of medical devices in Vietnam. With competition intensifying in North America and Europe, vendors focusing on localized production, affordable devices, and healthcare education in emerging markets can achieve long-term, sustainable growth.

Sudden cardiac arrests (SCAs) remain a leading global cause of death, but low awareness, especially in developing nations, significantly limits defibrillator adoption. According to the Heart Rhythm Society, over 60% of African Americans with heart disease symptoms do not seek medical care, reflecting a broader issue in emerging markets where high treatment costs, illiteracy, and poor healthcare access undermine awareness and response. CPR training alone can reduce out-of-hospital cardiac arrest mortality by 7.5%, yet training remains scarce in many regions. High device costs and limited public health budgets restrict uptake, leaving defibrillators largely unavailable in public spaces. Addressing these barriers through education, financing, and infrastructure is critical to improving survival rates and expanding global access to cardiac care.